Explore / Preprint
Preprint

Effects of cannabis use on antidepressant treatment response to repetitive transcranial magnetic stimulation and ketamine

Shenasa MAiD, Afshar HT, Miller EA, Ellerman-Tayag E, Mishra J, Ramanathan D

Jun 29, 20230 citationsDOI: 10.1101/2023.06.28.23291446

Abstract

<h4>Background</h4> The antidepressant effects of ketamine and repetitive transcranial magnetic stimulation (rTMS) are hypothesized to rely on mechanisms of long-term-potentiation and synaptic plasticity. Cannabis, via activation of CB1 receptors has been shown to impair synaptic plasticity, suggesting that cannabis use might moderate the antidepressant effects of ketamine and/or rTMS. <h4>Methods</h4> We performed a retrospective chart review of 222 Veterans, including 58 females, treated for depression with either rTMS or ketamine/esketamine at the VA San Diego Medical Center (VASDMC). We estimated the effects of treatment using changes in the Patient-Health-Questionnaire 9 (PHQ-9) split by cannabis use. Cannabis use was determined using self-report for rTMS (102 total, 23 screening positive for cannabis use) or urinary drug screens for ketamine (120 total, 40 screening positive for cannabis use). Mixed-level repeated measures ANOVA was utilized to determine whether cannabis use affected PHQ-9 scores (group effect) or the change in PHQ-9 over time (group x time interaction). <h4>Results</h4> Cannabis use did not affect overall symptom severity (group effect F (1, 100) = 0.58, p = 0.45) for rTMS, group effect (F (1, 118) = 0.58, p = 0.45) for ketamine, nor did it impact changes in symptoms for either treatment (group x time effect for ketamine: (F (7, 759) = 0.36, p = 0.93); group x time effect for rTMS (F (5, 412) = 0.4160, p = 0.83). <h4>Conclusions</h4> Cannabis use was unrelated to antidepressant treatment outcomes for either rTMS or ketamine, suggesting that cannabis use should not be a contraindication for these treatments.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.